Prevnar 20 (pneumococcal 20-valent conjugate vaccine) / Pfizer - LARVOL DELTA

An Italian cost-utility analysis of 20-Valent pneumococcal conjugate vaccine for routine vaccination in infants. (PubMed, J Med Econ) - "The introduction of PCV20 as a vaccination strategy for children in Italy represents a cost-effective and clinically advantageous option. Its implementation can reduce the burden of pneumococcal disease and associated healthcare costs, improving public health outcomes and the economic efficiency of the healthcare system."

HEOR • Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants (clinicaltrials.gov) - P2 | N=421 | Active, not recruiting | Sponsor: Inventprise Inc. | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2026

Enrollment closed • Trial completion date • Infectious Disease • Pneumococcal Infections

0100 - INDUSTRY SYMPOSIUM 04 (NOT INCLUDED IN THE MAIN EVENT CME/CPD CREDIT): From Data to Vaccination: Understanding the Science and Need for PCV20 (ESPID 2025) - "A panel of leading experts will examine the evolving epidemiology of pediatric pneumococcal disease, the critical need for broader serotype coverage, and the anticipated impact of next-generation pneumococcal conjugate vaccines (PCVs). With a particular focus on PCV20, discussions will highlight the pressing need for its timely implementation in national immunization programs to address gaps in protection and prevent unnecessary disease burden."

CME • Infectious Disease • Pediatrics • Pneumococcal Infections

Indirect Comparison of PCV20 Immunogenicity with PCV10 in Pediatric 3 + 1 and 2 + 1 Schedules. (PubMed, Infect Dis Ther) - "The comparable immunogenicity of PCV20 versus PCV10 in 2 + 1 and 3 + 1 schedules suggests that PCV20 will have similar effectiveness for the ten serotypes included in both vaccines, including for direct protection during infancy and toddler age, while also expanding serotype coverage. Effectiveness for PCV20 needs to be confirmed in post-marketing studies."

Journal • Infectious Disease • Pediatrics • Pneumococcal Infections • Pneumonia

A Study to Learn About How a New Pneumococcal Vaccine Works in Infants (clinicaltrials.gov) - P2 | N=800 | Recruiting | Sponsor: Pfizer | N=500 ➔ 800 | Trial completion date: Aug 2026 ➔ May 2027 | Trial primary completion date: Aug 2026 ➔ May 2027

Enrollment change • Trial completion date • Trial primary completion date • Infectious Disease • Pneumococcal Infections

PCV20 for the prevention of invasive pneumococcal disease in the Mexican pediatric population: A cost-effectiveness analysis. (PubMed, Hum Vaccin Immunother) - "The DSA, PSA, and scenario assessments confirmed minimal deviation from the base case. Therefore, the introduction of PCV20 (2 + 1) into the Mexican pediatric NIP is expected to reduce the burden of PD and medical costs compared with lower-valent alternatives."

HEOR • Journal • Infectious Disease • Pediatrics • Pneumococcal Infections

IS39 - Fighting foes, old and new: maintaining and expanding direct protection against persistent and emerging serotypes in adults with pneumococcal vaccination (ESCMID Global 2025) - "Pneumococcal vaccination with PCV20 can help reduce the burden of vaccine preventable respiratory diseases by providing direct protection against some of the most clinically relevant pneumococcal serotypes causing disease in adults. In this symposium we will discuss the evolving epidemiological pneumococcal landscape and how higher valent vaccines can help ensure maintenance and expanded coverage of some of the serotypes that cause a significant burden of disease in vulnerable populations."

Clinical • Pneumococcal vaccines • Infectious Disease • Pneumococcal Infections • Respiratory Diseases

Advancing Health Economics: Incorporating AMR Impact Into Pneumococcal Vaccine Assessment (ISPOR 2025) - "This pragmatic modelling approach effectively demonstrates the significant potential of PCV infant immunization in reducing antibiotic prescriptions and resistance. Additionally, the framework has identified key data gaps necessary for improving future modelling efforts. These findings advocate for the inclusion of AMR into cost-effectiveness models and to incorporate AMR impact into the health technology assessment and appraisals of vaccines."

HEOR • Pneumococcal vaccines • Infectious Disease • Pneumococcal Infections

Meta-analysis of Economic Evaluations of Higher-Valent Pneumococcal Conjugate Vaccines For Seniors in High-Income Countries (ISPOR 2025) - "This study suggests that higher-valent PCVs are generally cost-effective for the senior population in high-income countries, including PCV20 relative to PCV15. These findings can provide valuable insights for vaccination policy decisions in regions contemplating the use of higher-valent PCVs for older adults, supporting the efficient allocation of healthcare resources."

HEOR • Retrospective data • Infectious Disease • Pneumococcal Infections

A phase 3 study of 20-valent pneumococcal conjugate vaccine in healthy toddlers previously vaccinated in infancy with 13-valent pneumococcal conjugate vaccine. (PubMed, Vaccine) - P3 | "The safety and tolerability profile of PCV20 was similar to PCV13. Trial registration:Clinicaltrials.gov, NCT05408429."

Journal • P3 data • Infectious Disease • Pneumococcal Infections

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older (clinicaltrials.gov) - P=N/A | N=22234435 | Active, not recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Real-world evidence • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Insights into Insurance for Vaccine Coverage Patients on Specialty Medications (CRA-AHPA 2025) - "Full vaccination in the public insurance group were as follows: Influenza (81/132, 61.4%), COVID-19 (99/132, 75.0%), Prevnar 13 or 20 (75/132, 56.8%), Pneumovax 23 (106/132, 80.3%), and Shingrix (41/132, 31.1%). Overall, there were several important findings. The group with the highest vaccination rate across all categories were those possessing two or more insurance plans. Higher rates of influenza and Pneumovax 23 vaccination were seen in the public insurance group, but this is likely due to a majority of this group being older than 65 (age required for free Pneumovax coverage) and the general trend of increased influenza vaccination in older adults.[2] Prevnar and Shingrix vaccination rates were seemingly similar for public and private groups, however sub-group analysis presented an important finding."

Clinical • Reimbursement • US reimbursement • Herpes Zoster • Immunology • Infectious Disease • Inflammatory Arthritis • Influenza • Novel Coronavirus Disease • Pneumonia • Respiratory Diseases • Rheumatology • Varicella Zoster

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Recruiting | Sponsor: Sanofi | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Pneumococcal Pneumonia Vaccine Series (PCV20 and PPSV23) in Patients With Chronic Lymphocytic Leukemia Associated Immunodeficiency, PROTECT CLL Trial (clinicaltrials.gov) - P2 | N=60 | Recruiting | Sponsor: University of Utah | Trial completion date: Jan 2027 ➔ Jan 2028 | Trial primary completion date: Jan 2025 ➔ Jan 2026

Trial completion date • Trial primary completion date • Chronic Lymphocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pneumococcal Infections • Pneumonia • Respiratory Diseases • Small Lymphocytic Lymphoma

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=2320 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age (clinicaltrials.gov) - P3 | N=580 | Not yet recruiting | Sponsor: Sanofi

New P3 trial • Infectious Disease • Pneumococcal Infections

Economic Evaluation of Transitioning to the 20-Valent Pneumococcal Conjugate Vaccine in the Dutch Paediatric National Immunisation Programme. (PubMed, Infect Dis Ther) - "This cost-effectiveness analysis demonstrated that switching from PCV15 2 + 1 to PCV20 3 + 1 in the Dutch paediatric NIP would reduce both the clinical burden and projected costs of pneumococcal disease over 10 years."

HEOR • Journal • Infectious Disease • Pediatrics • Pneumococcal Infections

Delayed Transition to 20-Valent Pneumococcal Conjugate Vaccine in Pediatric National Immunization Programs: Forgone Public Health and Economic Benefit. (PubMed, Infect Dis Ther) - "Delays in implementing PCV20 into pediatric NIPs were projected to have substantial negative public health and economic consequences. These results underscore the necessity for national immunization technical advisory groups, policymakers, health organizations, and manufacturers to accelerate replacement of lower-valent standard-of-care PCVs with PCV20."

HEOR • Journal • Infectious Disease • Pediatrics • Pneumococcal Infections

Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants (clinicaltrials.gov) - P2 | N=420 | Recruiting | Sponsor: Inventprise Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • Infectious Disease • Pneumococcal Infections

Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants (clinicaltrials.gov) - P2 | N=420 | Not yet recruiting | Sponsor: Inventprise Inc.

New P2 trial • Infectious Disease • Pneumococcal Infections

A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months (clinicaltrials.gov) - P=N/A | N=1100 | Active, not recruiting | Sponsor: Pfizer | Not yet recruiting ➔ Active, not recruiting

Enrollment closed • Infectious Disease • Pneumococcal Infections

Factors Affecting Revaccination after Blood and Marrow Transplant (TCT-ASTCT-CIBMTR 2025) - "The replacement of Prevnar 13 with Prevnar 20 in 2021 to vaccinate against pneumococcal disease provided an opportunity to study vaccine-stimulated antibody response and identify patient characteristics correlating to protective antibody levels. LTFU nurses may provide individual navigation assistance, but additional work is needed to comprehensively improve the revaccination process for BMT patients and improve vaccination rates, promoting best outcomes for transplant patients. A centralized vaccine resource is now being explored to enhance regional vaccine resources."

Graft versus Host Disease • Immunology • Infectious Disease • Oncology • Pneumococcal Infections • Transplantation

A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older (clinicaltrials.gov) - P=N/A | N=22234435 | Not yet recruiting | Sponsor: Pfizer

New trial • Real-world evidence • Infectious Disease • Pneumococcal Infections • Pneumonia • Respiratory Diseases

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants (clinicaltrials.gov) - P3 | N=1196 | Completed | Sponsor: GlaxoSmithKline | Active, not recruiting ➔ Completed | Trial completion date: May 2025 ➔ Dec 2024

Trial completion • Trial completion date • Infectious Disease • Meningococcal Infections • Pneumococcal Infections